IRESSA
Total Payments
$3.8M
Transactions
505
Doctors
209
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $38,469 | 4 | 0 |
| 2023 | $63,289 | 12 | 3 |
| 2022 | $34,000 | 13 | 2 |
| 2021 | $37,079 | 11 | 4 |
| 2020 | $2.9M | 25 | 11 |
| 2019 | $210,095 | 82 | 37 |
| 2018 | $160,621 | 118 | 57 |
| 2017 | $293,203 | 240 | 147 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $3.8M | 110 | 99.8% |
| Food and Beverage | $6,038 | 368 | 0.2% |
| Space rental or facility fees (teaching hospital only) | $2,325 | 4 | 0.1% |
| Education | $742.80 | 23 | 0.0% |
Payments by Type
Research
$3.8M
110 transactions
General
$9,106
395 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Phase I trial of AZD9291 in combination | AstraZeneca Pharmaceuticals LP | $2.9M | 0 |
| IRESSA PD L1 combination Phase 1 study | AstraZeneca Pharmaceuticals LP | $447,172 | 0 |
| IRESSA US Clinical Access Program CAP | AstraZeneca Pharmaceuticals LP | $221,597 | 0 |
| Children';s Hospitals and Clinics of Minnesota-Single Patient Use of Iressa for Patient B.S. | AstraZeneca Pharmaceuticals LP | $91,857 | 0 |
| Children's Hospitals and Clinics of Minnesota-Single Patient Use of Iressa for Patient B.S. | AstraZeneca Pharmaceuticals LP | $46,271 | 0 |
| IRESSA ICAP chart review | AstraZeneca Pharmaceuticals LP | $43,418 | 1 |
Top Doctors Receiving Payments for IRESSA — Page 9
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , M.D | Specialist | Ponce, PR | $6.21 | 1 |
| , MD | Hematology & Oncology | Easton, PA | $6.21 | 1 |
| , M.D | Hematology & Oncology | Coral Gables, FL | $4.20 | 1 |
| , M.D | Hematology | Sarasota, FL | $3.84 | 1 |
| , M.D | Hematology & Oncology | Bryan, TX | $3.84 | 1 |
| , MD | Internal Medicine | Shreveport, LA | $3.04 | 1 |
| , M. D | Hematology & Oncology | Franklin, WI | $2.30 | 1 |
| , M.D | Plastic Surgery within the Head & Neck | Brookfield, WI | $2.30 | 1 |
| , MD | Medical Oncology | San Francisco, CA | $2.30 | 1 |
| , MD | Hematology & Oncology | Hutchinson, KS | $1.28 | 1 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $3.8M
- Total Doctors 209
- Transactions 505
About IRESSA
IRESSA is a drug associated with $3.8M in payments to 209 healthcare providers, recorded across 505 transactions in the CMS Open Payments database. The primary manufacturer is AstraZeneca Pharmaceuticals LP.
Payment data is available from 2017 to 2024. In 2024, $38,469 was paid across 4 transactions to 0 doctors.
The most common payment nature for IRESSA is "Unspecified" ($3.8M, 99.8% of total).
IRESSA is associated with 6 research studies, including "Phase I trial of AZD9291 in combination" ($2.9M).